Aspirin labeling for M-I prevention
This article was originally published in The Tan Sheet
Executive Summary
FDA has enlisted the Aspirin Foundation of America to coordinate submissions of certain foreign studies that looked at aspirin for the prevention of cardiovascular events following an acute myocardial infarction, according to an agency memo of an April 26 meeting between AFA and FDA. Once the data are submitted in proper form, FDA said it will begin working on a notice that would propose prescription labeling for the prophylactic use of aspirin.